<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Staging of immunoglobulin light chain (AL) amyloidosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Staging of immunoglobulin light chain (AL) amyloidosis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Staging of immunoglobulin light chain (AL) amyloidosis</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="22%"></colgroup><colgroup width="12%"></colgroup><colgroup span="2" width="22%"></colgroup> <tbody> <tr> <td class="subtitle1">Model</td> <td class="subtitle1">Risk factor thresholds</td> <td class="subtitle1" colspan="2">Stage</td> <td class="subtitle1">Hazard ratio for death<br/> (95% CI)*</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Mayo 2004<sup>[1]</sup></td> <td class="divider_bottom" rowspan="3"> <ol class="numbers_to_nine"> <li>Troponin: <ul> <li>Cardiac TnT ≥0.035 mcg/L<br/> <strong>or</strong></li> <li>Cardiac TnI ≥0.1 mcg/L<br/> <strong>or</strong></li> <li>High sensitivity cardiac TnT ≥50 ng/L</li> </ul> </li> <li>BNP: <ul> <li>NT-proBNP ≥332 ng/L<br/> <strong>or</strong></li> <li>BNP ≥81 ng/L</li> </ul> </li> </ol> </td> <td>Stage I</td> <td>No risk factors</td> <td>Reference</td> </tr> <tr> <td>Stage II</td> <td>1 risk factor</td> <td>2.5 (1.9-3.5)</td> </tr> <tr class="divider_bottom"> <td>Stage III</td> <td>2 risk factors</td> <td>6.7 (5.0-9.1)</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Mayo 2004 with European modification<sup>[2]</sup></td> <td class="divider_bottom" rowspan="4"> <ol class="numbers_to_nine"> <li>Troponin: <ul> <li>Cardiac TnT ≥0.035 mcg/L<br/> <strong>or</strong></li> <li>Cardiac TnI ≥0.1 mcg/L<br/> <strong>or</strong></li> <li>High sensitivity cardiac TnT ≥50 ng/L</li> </ul> </li> <li>BNP: <ul> <li>NT-proBNP ≥332 ng/L<br/> <strong>or</strong></li> <li>BNP ≥81 ng/L</li> </ul> </li> </ol> </td> <td>Stage I</td> <td>No risk factors</td> <td>Reference</td> </tr> <tr> <td>Stage II</td> <td>1 risk factor</td> <td>2.5 (1.9-3.5)</td> </tr> <tr> <td>Stage IIIA</td> <td> <p>2 risk factors</p> <p>NT-proBNP 332 to &lt;8500 ng/L or BNP 81 to &lt;700 ng/L</p> </td> <td>4.9 (3.6-6.8)</td> </tr> <tr class="divider_bottom"> <td>Stage IIIB</td> <td> <p>2 risk factors</p> <p>NT-proBNP ≥8500 ng/L or BNP ≥700 ng/L</p> </td> <td>11.1 (8.1-15.4)</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Mayo 2012<sup>[3]</sup></td> <td class="divider_bottom" rowspan="4"> <ol class="numbers_to_nine"> <li>Troponin <ul> <li>Cardiac troponin T ≥0.025 mcg/L<br/> <strong>or</strong></li> <li>High sensitivity cardiac troponin T ≥40 ng/L</li> </ul> </li> <li>BNP: <ul> <li>NT-proBNP ≥1800 ng/L<br/> <strong>or</strong></li> <li>BNP ≥400 ng/L</li> </ul> </li> <li>dFLC ≥18 mg/dL</li> </ol> </td> <td>Stage I</td> <td>No risk factors</td> <td>Reference</td> </tr> <tr> <td>Stage II</td> <td>1 risk factor</td> <td>1.7 (1.2-2.3)</td> </tr> <tr> <td>Stage III</td> <td>2 risk factors</td> <td>4.1 (3.1-5.5)</td> </tr> <tr class="divider_bottom"> <td>Stage IV</td> <td>3 risk factors</td> <td>6.3 (4.8-8.3)</td> </tr> <tr> <td rowspan="4">Boston University<sup>[4]</sup></td> <td rowspan="4"> <ol class="numbers_to_nine"> <li>Troponin: <ul> <li>Cardiac troponin I &gt;0.10 ng/mL</li> </ul> </li> <li>BNP: <ul> <li>BNP &gt;81 pg/mL</li> </ul> </li> </ol> </td> <td>Stage I</td> <td>No risk factors</td> <td>Median OS &gt;12 years</td> </tr> <tr> <td>Stage II</td> <td>1 risk factor</td> <td>Median OS 9.4 years</td> </tr> <tr> <td>Stage IIIA</td> <td> <p>2 risk factors</p> <p>BNP &gt;81 pg/mL</p> </td> <td>Median OS 4.3 years</td> </tr> <tr> <td>Stage IIIB</td> <td> <p>2 risk factors</p> <p>BNP &gt;700 pg/mL</p> </td> <td>Median OS 1 year</td> </tr> </tbody></table></div><div class="graphic_footnotes">TnT: troponin T; TnI: troponin I; BNP: brain natriuretic peptide; NT-proBNP: N-terminal pro-brain natriuretic peptide; dFLC: difference between involved and uninvolved serum free light chains; OS: overall survival.<br/>* Hazard ratios presented reflect use of cardiac troponin T and NT-proBNP.</div><div class="graphic_reference">References:

	<ol>
<li>Dispenzieri A, Gertz M, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751.</li>
<li>Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015; 126:612.</li>
<li>Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30:989.</li>
<li>Lilleness B, Ruberg FL, Mussinelli R, et al. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 2019; 133:215.</li>
</ol>

	Adapted from: Muchtar E, Kumar SK, Gertz M, et al. Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood 2019; 133:763.</div><div id="graphicVersion">Graphic 130978 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
